Featured Editorial

  1. Will 2027 See A Meteoric Rise Of Programmable Nanomedicine? 9/2/2026

    The significance of programmable nanomedicines is not simply that nanoparticles can carry more functions. It is that biological information can become part of the control logic.

  2. What Baby KJ Taught Us About Patient & Physician Communication 9/1/2026

    Over the past few weeks, I’ve been sharing my takeaways from the overall event, as well as from a specific panel featuring JHU’s Jeff Coller, CHOP’s Rebecca Ahrens-Nicklas, and Plowshare Therapies’ Kevin Strauss. Together, these three discussed the biggest learnings and takeaways from the miraculous Baby KJ experience that we very much hope to replicate in the future. As you can likely imagine, patient and physician communication played a large role in the discussion at hand. 

  3. From Cell State Reprogramming To The Clinic: Turning The Regulatory Genome Into RNA Medicines (Pt. 2) 8/26/2026

    Ounzain discusses how regulatory genome biology is being translated into drug discovery, from identifying lncRNA targets to building clinically relevant therapeutics and more.

  4. What Baby KJ Taught Us About mRNA COGS 8/25/2026

    Here, in part 2 of this three-part series, I share a few details that came to light about the COGS behind Baby KJ’s therapy production. Obviously, we know why it’s important to keep these figures in mind as we move forward; but I particularly liked Strauss’ reminder that it’s our job to “think systematically about how we’re going to create a safety net of sustainable, accessible product that can be widely distributed at an affordable cost.”

  5. Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics 8/19/2026

    Emerging therapies are being designed to safely deliver oligonucleotides to disease-relevant tissues. Delivery is no longer a technical hurdle to overcome but a strategic lever.

  6. Drugging The tRNA Control System 8/19/2026

    Drug discovery has usually treated transfer RNA as cellular infrastructure: indispensable, highly conserved, and therefore dangerous to perturb. That description is accurate but incomplete. 

  7. What Baby KJ Taught Us About Sustainable mRNA Development 8/18/2026

    Of course, these conversations are rarely simple, and the learnings are multifaceted. In the following three-part series, I’ll share my 3 biggest takeaways from the discussion between Coller, Ahrens-Nicklas, and Strauss. Here in part 1, I’ll start by parsing out the learnings about drug development we can take away from the overall heroic efforts to dose Baby KJ. 

  8. Analytical Platforms: The Foundation Of The Next Generation Of RNA Therapeutics 8/11/2026

    RNA therapeutics are entering a new era where analytical platforms drive scalability, regulatory confidence, manufacturing flexibility, and the development of increasingly complex products.

  9. A New Purification Strategy For The Removal Of dsRNA Impurities From IVT mRNA Products 8/10/2026

    NIST research introduces a gentle SEC method that separates dsRNA impurities from IVT mRNA by tweaking buffer pH, achieving 81.8% target recovery without transcript damage.

  10. The Second Holy Grail Of Gene Editing: Large Knock-Ins 8/10/2026

    Exploring the race to achieve large gene knock-ins, emerging editing platforms, and how overcoming this challenge could unlock therapies for many inherited diseases.